Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Eosinophilic Asthma Clear all

Conditions: Asthma
Interventions: Reslizumab, Saline; Biological · Other
Lead sponsor: Ception Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 24
States / cities: Orange, California • Centennial, Colorado • Colorado Springs, Colorado + 20 more

Conditions: Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
Interventions: benralizumab, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Asthma
Interventions: Benralizumab; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Allergy, Asthma, Allergic Rhinitis, Mastocytosis, Atopic Dermatitis, Food Allergy
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 80 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Asthma
Interventions: Mepolizumab, SOC; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 16
States / cities: Newport Beach, California • Riverside, California • Rolling Hills Estates, California + 13 more

Conditions: Eosinophilic Asthma
Interventions: Reslizumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 26
States / cities: Scottsdale, Arizona • Los Angeles, California • Orange, California + 23 more

Conditions: Eosinophilic Asthma
Interventions: ICS-LABA, benralizumab, Placebo for Benralizumab; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 20
States / cities: Sun City, Arizona • Tucson, Arizona • Inglewood, California + 17 more

Conditions: Eosinophilic Asthma
Interventions: Observational; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Eosinophilic Asthma
Interventions: Etokimab, Placebo; Biological · Drug
Lead sponsor: AnaptysBio, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Normal, Illinois • Novi, Michigan • Edmond, Oklahoma + 1 more

Conditions: Eosinophilic Asthma
Interventions: Reslizumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 66
States / cities: Birmingham, Alabama • Homewood, Alabama • Jasper, Alabama + 58 more

Conditions: Asthma
Interventions: GSK3511294 (Depemokimab); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 29
States / cities: Mobile, Alabama • Lancaster, California • Colorado Springs, Colorado + 23 more

Conditions: Asthma
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more

Conditions: Asthma
Interventions: Reslizumab, Fludeoxyglucose F 18 (FDG), Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Interventions: Dexpramipexole Dihydrochloride, Placebo; Drug
Lead sponsor: Areteia Therapeutics; Industry
Eligibility: 12 Years to 99 Years
Enrollment: 1,061 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 89
States / cities: Bakersfield, California • La Palma, California • Newport Beach, California + 73 more

Conditions: Asthma
Interventions: Lebrikizumab, Placebo, Inhaled corticposteroids (ICS), Second Asthma Controller Medication; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 16
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 12 more

Conditions: Immune Deficiency, Immune Dysregulation Disorder, Allergic Inflammation
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: Up to 99 Years
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Eosinophilic Esophagitis
Interventions: APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy; Drug · Procedure
Lead sponsor: Ellodi Pharmaceuticals, LP; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 59
States / cities: Dothan, Alabama • Mobile, Alabama • Scottsdale, Arizona + 54 more

Conditions: Eosinophilic Asthma
Interventions: KT-621, Placebo; Drug · Other
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 34
States / cities: Lancaster, California • Long Beach, California • Northridge, California + 28 more

Conditions: Asthma
Interventions: Reslizumab; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Asthma
Interventions: Mepolizumab 100mg SC, Albuterol/salbutamol MDIs, Omalizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 13
States / cities: Birmingham, Alabama • Riverside, California • Roseville, California + 10 more

Conditions: Eosinophils, Asthma
Interventions: reslizumab; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 37
States / cities: Birmingham, Alabama • Bakersfield, California • Huntington Beach, California + 31 more

Conditions: Asthma
Interventions: GB001, Placebo; Drug
Lead sponsor: GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 47
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 41 more

Conditions: Food Allergy, Asthma, Allergic Rhinitis, Atopic Dermatitis, Eosinophilic Esophagitis
Interventions: Not listed
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 1 Year to 17 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Asthma
Interventions: GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS); Biological · Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 1,717 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 119
States / cities: Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more

Search by objective public record fields.

Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders

A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma

Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma

Allergy and Immunology Natural History Study

24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients

A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma

GB001 in Adult Subjects With Moderate to Severe Asthma

Assessing Risk of Food Insecurity Within Households of Children With Food Allergy

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype